Last reviewed · How we verify
Chong Kun Dang Tofacitinib Tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Chong Kun Dang Tofacitinib Tablet (Chong Kun Dang Tofacitinib Tablet) — Chong Kun Dang Pharmaceutical.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Chong Kun Dang Tofacitinib Tablet TARGET | Chong Kun Dang Tofacitinib Tablet | Chong Kun Dang Pharmaceutical | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Chong Kun Dang Tofacitinib Tablet CI watch — RSS
- Chong Kun Dang Tofacitinib Tablet CI watch — Atom
- Chong Kun Dang Tofacitinib Tablet CI watch — JSON
- Chong Kun Dang Tofacitinib Tablet alone — RSS
Cite this brief
Drug Landscape (2026). Chong Kun Dang Tofacitinib Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/chong-kun-dang-tofacitinib-tablet. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab